Semaglutide reduces risk of kidney decline or death in type 2 diabetes and CKD
Semaglutide lowers kidney and heart risks in type 2 diabetes patients
This randomized controlled trial enrolled 3,533 participants with type 2 diabetes and chronic kidney disease. Once-weekly subcutaneous semag…
A large trial shows once-weekly semaglutide reduces kidney failure and death risks in people with type 2 diabetes and chronic kidney disease…
Semaglutide associated with 35.2% of weight loss as lean mass versus 26.2% with lifestyle interventions
New analysis shows weight loss drugs and lifestyle changes affect muscle loss similarly
This systematic review and meta-analysis evaluated 15 782 adults with overweight or obesity receiving incretin-based therapies or intensive …
A large review of 15,782 adults found that weight loss drugs and lifestyle changes led to similar proportions of muscle loss during weight r…
Semaglutide use may be associated with kidney damage in 20 cases across 18 studies
Semaglutide may harm kidneys in rare cases, doctors warn
This systematic review synthesizes data from 18 studies involving 20 cases of kidney injury linked to semaglutide. Among these cases, 17 pat…
A review of 20 cases found that semaglutide use was linked to kidney injury, with most patients recovering but some not.
Tirzepatide maximum tolerated dose leads weight reduction ranking in obesity network meta-analysis
New analysis shows weight loss drugs work best for adults with obesity without diabetes
This systematic review and network meta-analysis of 14,059 adults with obesity without diabetes ranked GLP-1 receptor agonists and a dual ag…
A large review of many studies found that specific injectable medicines help adults lose weight. Tirzepatide worked best, but all options re…
Semaglutide Improves Metabolic Health in Schizophrenia Patients on Antipsychotics
Semaglutide improves blood sugar and weight in people with schizophrenia and prediabetes
A randomized, placebo-controlled trial in 154 overweight or obese individuals with schizophrenia and prediabetes receiving second-generation…
A new trial shows semaglutide helps lower blood sugar and reduce weight in people with schizophrenia who also have prediabetes or obesity.
GLP-1 receptor agonists show no increased ocular disorder risk in type 2 diabetes meta-analysis
New analysis shows GLP-1 drugs do not raise eye disease risk for diabetes patients
This systematic review and meta-analysis of 28 observational studies found that GLP-1 receptor agonists did not increase the risk of NAION, …
A large review of 28 studies found that diabetes drugs called GLP-1 receptor agonists do not increase the risk of eye problems like glaucoma…
Semaglutide 1.7 mg shows comparable BMI reduction to 2.4 mg in adolescents and adults
Lower-dose semaglutide works as well as higher doses for teen and adult obesity
This model-informed analysis combined Phase 3 adolescent and adult semaglutide trial data. Semaglutide 1.7 mg produced a mean BMI change com…
A new analysis shows that a lower dose of semaglutide works just as well as the higher dose for weight loss in teens and adults, with simila…
Cagrisema produces greater weight loss than semaglutide in obesity meta-analysis
New analysis shows cagrisema beats semaglutide for weight loss in obesity
This systematic review and meta-analysis of 3,545 individuals with obesity found that cagrisema produced significantly greater weight loss t…
A large meta-analysis found cagrisema produced greater weight loss than semaglutide, while cagrilintide alone matched semaglutide results in…
Oral Semaglutide Failed to Slow Clinical Progression in Early Alzheimer's Disease Across Global Phase 3 Trials
Oral semaglutide did not slow Alzheimer's disease progression in early trials
In large phase 3 trials, oral semaglutide showed no benefit over placebo for patients with early Alzheimer's disease. The drug did not impro…
A large trial found that taking oral semaglutide offered no benefit over placebo for people with early Alzheimer's disease.
CagriSema demonstrates superior weight loss efficacy compared to semaglutide monotherapy or placebo in obesity trials
New drug combo beats standard treatment for obesity and heart risks
A systematic review and meta-analysis of 4,419 patients reveals CagriSema drives greater weight loss than semaglutide alone. However, clinic…
This new drug combination helps people lose more weight and lowers blood pressure, but it causes more stomach upset that needs careful watch…
Bayesian network meta-analysis compares tirzepatide, liraglutide, and semaglutide for weight reduction in adults without diabetes
New Weight Loss Drug Beats Popular Options in Head-to-Head Comparison
This Bayesian network meta-analysis synthesized evidence from 42 randomized controlled trials, six of which were included in the network, to…
A newer weight loss drug helped people drop nearly 14 percent of their body weight, beating two popular options in a major comparison.
Network Meta-Analysis Finds Tirzepatide and Sleeve Gastrectomy Equally Effective for Weight Loss in Obesity
New Weight Loss Pill Matches Surgery Results Without the Scalpel
A network meta-analysis of 14,293 adults with obesity found that tirzepatide 10 or 15 mg and sleeve gastrectomy achieved similar weight loss…
A diabetes drug now pulls even with stomach surgery for weight loss offering hope to millions who dread going under the knife but it is not …
All semaglutide Articles
- Semaglutide reduces risk of kidney decline or death in type 2 diabetes and CKD
- Semaglutide use may be associated with kidney damage in 20 cases across 18 studies
- Semaglutide associated with 35.2% of weight loss as lean mass versus 26.2% with lifestyle interventions
- Semaglutide Improves Metabolic Health in Schizophrenia Patients on Antipsychotics
- Tirzepatide maximum tolerated dose leads weight reduction ranking in obesity network meta-analysis
- GLP-1 receptor agonists show no increased ocular disorder risk in type 2 diabetes meta-analysis
- Semaglutide 1.7 mg shows comparable BMI reduction to 2.4 mg in adolescents and adults
- Cagrisema produces greater weight loss than semaglutide in obesity meta-analysis
- Oral Semaglutide Failed to Slow Clinical Progression in Early Alzheimer's Disease Across Global Phase 3 Trials
- CagriSema demonstrates superior weight loss efficacy compared to semaglutide monotherapy or placebo in obesity trials
- Bayesian network meta-analysis compares tirzepatide, liraglutide, and semaglutide for weight reduction in adults without diabetes
- Network Meta-Analysis Finds Tirzepatide and Sleeve Gastrectomy Equally Effective for Weight Loss in Obesity
- GLP-1 receptor agonists show greater weight loss in women than men across multiple trials
- Tirzepatide improves standard and intensive therapeutic target attainment versus semaglutide in adults with type 2 diabetes
- Semaglutide improves physical quality of life in schizophrenia with prediabetes
- Semaglutide reduces insulin dose in adults with type 1 diabetes and obesity
- Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity
- Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
- GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates
- Baseline vitamin D levels linked to semaglutide glycemic and weight outcomes in type 2 diabetes
- Semaglutide high dose for weight reduction in people with Type 2 Diabetes
- PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic Medications
- Review of observational data links semaglutide and tirzepatide to survival in breast cancer
- Network Meta-Analysis Finds Tirzepatide and Semaglutide Most Effective for Weight Loss in Adults
- Computational model review predicts dual optima for combination therapy in ageing
- Semaglutide linked to lower neuropsychiatric event risk vs other diabetes drugs in observational study
- Narrative review compares tirzepatide and semaglutide for obesity and type 2 diabetes outcomes
- Tirzepatide MTD Demonstrates Cost-Effectiveness Versus Semaglutide MTD in Obesity Simulation Modeling Study
- Review of new-user target trial emulation comparing semaglutide and SGLT2i in U.S. Veterans with type 2 diabetes
- Monitoring report on US GLP-1 RA prescribing trends shows increased oral semaglutide use
- Observational study links semaglutide dose and weight loss to lower liver disease risk
- GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT
- Tirzepatide shows greater lean body mass loss than semaglutide in first-episode GLP-1RA users with type 2 diabetes
- Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD
- Orforglipron shows superior HbA1c reduction versus oral semaglutide in adults with type 2 diabetes on metformin
- Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
- Narrative review assesses GLP-1 receptor agonists versus insulin for steroid-induced hyperglycemia and diabetes
- Oral semaglutide reduces composite heart failure outcomes in patients with type 2 diabetes and heart failure history
- Observational EHR study suggests GLP-1 RA may have lower risk than SGLT2i for HF outcomes
- Efruxifermin shows superior fibrosis regression in compensated MASH cirrhosis compared to placebo in a network meta-analysis
- GLP-1 receptor agonists associated with lower respiratory sequelae risk in case report analysis
- Phase 1b trial of oral GLP-1 agonist HDM1002 shows weight reduction in Chinese adults with overweight/obesity
- GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight
- New-onset diabetes in adults over 50 associated with higher pancreatic cancer risk within 3 years
- Network meta-analysis of pharmacotherapies shows GLP-1 RAs and SGLT2is reduce composite cardiovascular death and hospitalization in HFpEF
- Short-term liraglutide modulates proteins in obesity, showing weight-independent effects and myostatin suppression
- GLP-1 Receptor Agonist Use in Wolfram Syndrome Shows No Glycemic or BMI Benefit, Common GI Effects
- Post hoc analysis links WHtR threshold to remission in obesity management with tirzepatide vs semaglutide
- Pilot qualitative study explores pathways and acceptability of cash transfers for low-income patients with hypertension or diabetes
- Systematic review finds first FDA-approved CRISPR therapy and broader clinical trial exploration
- Bariatric surgery associated with lower cardiovascular risks than GLP-1RA therapy in adults with obesity
- GLP-1RAs associated with improved walking distance in diabetes with PAD, but limb event evidence uncertain
- GLP-1RA use associated with lower obesity-related cancer risk in meta-analysis of adults with T2DM/obesity
- GLP-1 receptor agonists reduce new-onset heart failure risk in patients with diabetes or obesity
- GLP-1RAs Show No Significant Motor Benefit in Parkinson's Disease Meta-Analysis
- Retrospective study of semaglutide in 17 patients with type 2 diabetes and end-stage renal disease
- FDA Approves Winrevair for Pulmonary Arterial Hypertension (PAH) in Adults